FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247146814> ?p ?o ?g. }

• W2247146814 endingPage "9002" @default.
• W2247146814 startingPage "9002" @default.
• W2247146814 abstract "9002 Background: Cancer-related-fatigue (CRF) is the most common and distressing symptoms in patients with advanced cancer. Currently, there is no standard treatment for CRF. Although corticosteroids have been used in the treatment of CRF, there are no well-powered placebo-controlled trials that used a validated CRF outcome measure. The primary objective of this prospective, randomized, double-blind, placebo-controlled study is to compare the effect of DM versus placebo on CRF. Methods: Advanced cancer patients with fatigue ≥ 4/10 on the Edmonton Symptom Assessment Scale (ESAS) and at least 2 other CRF-related symptoms (pain, nausea, appetite, depression, anxiety or sleep disturbance ≥ 4/10), normal cognition, no infections and hemoglobin ≥ 9 g/L were eligible for enrollment. Patients were randomized to either receive dexamethasone 4 mg orally twice a day for 15 days (primary end point) or matching placebo. The primary outcome was the day 15 change in Functional Assessment of Chronic Illness-Fatigue (FACIT-F) subscale scores. Differences in the group means (normal distribution) were analyzed using the two-sample t-test. Results: In 83 evaluable patients (43 DM and 40 placebo), median age was 60 years, 61% were white, and 53% were female. There was no difference in the demographics and fatigue (FACIT-F subscale) between DM and placebo groups except for sex (p=0.02). The mean (SD) FACIT-F subscores at baseline and at day 15 for DM were 18 (11) and 27 (11) (p<0.001) and for placebo were 21 (9) and 24 (12) (p=0.06), respectively. Mean improvement in FACIT-F subscale was significantly higher in the DM group compared to placebo (9.6 (11) vs. 3.1 (9.7), p=0.005). We found a significant difference in ESAS physical distress (p=0.02), but no differences in ESAS overall symptom distress (p=0.11) and ESAS psychological distress (P=0.88) between DM and placebo. There were insignificantly higher numbers of grade ≥3 toxicities in patients who received DM than in patients who received placebo (20/42 vs. 18/47, p=0.37). Conclusions: Dexamethasone was more effective than placebo in reducing CRF in patients with advanced cancer. Long-term safety studies are needed." @default.
• W2247146814 created "2016-06-24" @default.
• W2247146814 creator A5000071835 @default.
• W2247146814 creator A5002909822 @default.
• W2247146814 creator A5009177808 @default.
• W2247146814 creator A5014713051 @default.
• W2247146814 creator A5021570758 @default.
• W2247146814 creator A5031637028 @default.
• W2247146814 creator A5040423978 @default.
• W2247146814 creator A5047699558 @default.
• W2247146814 creator A5053287560 @default.
• W2247146814 creator A5054322875 @default.
• W2247146814 creator A5058115259 @default.
• W2247146814 creator A5058392144 @default.
• W2247146814 creator A5066360308 @default.
• W2247146814 creator A5069798271 @default.
• W2247146814 creator A5079828009 @default.
• W2247146814 creator A5087205593 @default.
• W2247146814 date "2012-05-20" @default.
• W2247146814 modified "2023-09-26" @default.
• W2247146814 title "Dexamethasone (DM) for cancer-related fatigue: A double-blinded, randomized, placebo-controlled trial." @default.
• W2247146814 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.9002" @default.
• W2247146814 hasPublicationYear "2012" @default.
• W2247146814 type Work @default.
• W2247146814 sameAs 2247146814 @default.
• W2247146814 citedByCount "10" @default.
• W2247146814 countsByYear W22471468142013 @default.
• W2247146814 countsByYear W22471468142014 @default.
• W2247146814 countsByYear W22471468142015 @default.
• W2247146814 countsByYear W22471468142016 @default.
• W2247146814 countsByYear W22471468142017 @default.
• W2247146814 countsByYear W22471468142022 @default.
• W2247146814 countsByYear W22471468142023 @default.
• W2247146814 crossrefType "journal-article" @default.
• W2247146814 hasAuthorship W2247146814A5000071835 @default.
• W2247146814 hasAuthorship W2247146814A5002909822 @default.
• W2247146814 hasAuthorship W2247146814A5009177808 @default.
• W2247146814 hasAuthorship W2247146814A5014713051 @default.
• W2247146814 hasAuthorship W2247146814A5021570758 @default.
• W2247146814 hasAuthorship W2247146814A5031637028 @default.
• W2247146814 hasAuthorship W2247146814A5040423978 @default.
• W2247146814 hasAuthorship W2247146814A5047699558 @default.
• W2247146814 hasAuthorship W2247146814A5053287560 @default.
• W2247146814 hasAuthorship W2247146814A5054322875 @default.
• W2247146814 hasAuthorship W2247146814A5058115259 @default.
• W2247146814 hasAuthorship W2247146814A5058392144 @default.
• W2247146814 hasAuthorship W2247146814A5066360308 @default.
• W2247146814 hasAuthorship W2247146814A5069798271 @default.
• W2247146814 hasAuthorship W2247146814A5079828009 @default.
• W2247146814 hasAuthorship W2247146814A5087205593 @default.
• W2247146814 hasConcept C126322002 @default.
• W2247146814 hasConcept C139719470 @default.
• W2247146814 hasConcept C142724271 @default.
• W2247146814 hasConcept C162324750 @default.
• W2247146814 hasConcept C168563851 @default.
• W2247146814 hasConcept C1862650 @default.
• W2247146814 hasConcept C204787440 @default.
• W2247146814 hasConcept C27081682 @default.
• W2247146814 hasConcept C2776867660 @default.
• W2247146814 hasConcept C2780401358 @default.
• W2247146814 hasConcept C2780580376 @default.
• W2247146814 hasConcept C71924100 @default.
• W2247146814 hasConceptScore W2247146814C126322002 @default.
• W2247146814 hasConceptScore W2247146814C139719470 @default.
• W2247146814 hasConceptScore W2247146814C142724271 @default.
• W2247146814 hasConceptScore W2247146814C162324750 @default.
• W2247146814 hasConceptScore W2247146814C168563851 @default.
• W2247146814 hasConceptScore W2247146814C1862650 @default.
• W2247146814 hasConceptScore W2247146814C204787440 @default.
• W2247146814 hasConceptScore W2247146814C27081682 @default.
• W2247146814 hasConceptScore W2247146814C2776867660 @default.
• W2247146814 hasConceptScore W2247146814C2780401358 @default.
• W2247146814 hasConceptScore W2247146814C2780580376 @default.
• W2247146814 hasConceptScore W2247146814C71924100 @default.
• W2247146814 hasIssue "15_suppl" @default.
• W2247146814 hasLocation W22471468141 @default.
• W2247146814 hasOpenAccess W2247146814 @default.
• W2247146814 hasPrimaryLocation W22471468141 @default.
• W2247146814 hasRelatedWork W1990941510 @default.
• W2247146814 hasRelatedWork W2070384222 @default.
• W2247146814 hasRelatedWork W2153052119 @default.
• W2247146814 hasRelatedWork W2170209256 @default.
• W2247146814 hasRelatedWork W2180449971 @default.
• W2247146814 hasRelatedWork W2334008906 @default.
• W2247146814 hasRelatedWork W261798218 @default.
• W2247146814 hasRelatedWork W3185137146 @default.
• W2247146814 hasRelatedWork W4256514411 @default.
• W2247146814 hasRelatedWork W4320892345 @default.
• W2247146814 hasVolume "30" @default.
• W2247146814 isParatext "false" @default.
• W2247146814 isRetracted "false" @default.
• W2247146814 magId "2247146814" @default.
• W2247146814 workType "article" @default.